SCHEMBL4716980

SCHEMBL4716980

CCOC(=O)c1cc2ncccc2n1Cc1ccc(F)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD2 Q9HC29 1/20 0.50
NOD1 Q9Y239 1/20 0.50
MAPT P10636 8/20 0.47
ALDH1A1 P00352 3/20 0.47
POLB P06746 2/20 0.47
HTT P42858 1/20 0.47
TDP1 Q9NUW8 4/20 0.46
KDM4E B2RXH2 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MAPK1 P28482 1/20 0.46
F10 P00742 4/20 0.46
TSHR P16473 3/20 0.43
ATM Q13315 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.42
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715565 0.90 NOD2 (0.51) NOD2NOD1MAPTALDH1A1POLB
SCHEMBL4714196 0.85 MAPT (0.60) NOD2NOD1MAPTALDH1A1POLB
SCHEMBL4714540 0.84 NOD2 (0.51) NOD2NOD1MAPTALDH1A1POLB
SCHEMBL4713839 0.84 NOD2 (0.53) NOD2NOD1MAPTALDH1A1POLB
SCHEMBL4715544 0.78 NOD2 (0.48) NOD2NOD1MAPTALDH1A1POLB
SCHEMBL18322260 0.77 KDM4E (0.49) NOD2NOD1MAPTALDH1A1POLB
SCHEMBL30489126 0.77 KDM4E (0.49) NOD2NOD1MAPTALDH1A1POLB
SCHEMBL2051278 0.76 PTGER4 (0.48) NOD2NOD1MAPTALDH1A1HTT
SCHEMBL4716178 0.75 MAPT (0.47) NOD2NOD1MAPTALDH1A1POLB
Hydrochloric Acid SCHEMBL30954491 0.75 KDM4E (0.42) NOD2NOD1MAPTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed
EP-1549648-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS Celltech R & D Limited (GB) 2005-07-06 EP disclosed
WO-2004031188-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 NOD2 138/4885NOD1 312/4885MAPT 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.